Pear Therapeutics raises $175M and goes public via SPAC deal raising the profile of prescription digital therapeutics

By SharpBrains | December 8, 2021

Dig­i­tal health firm Pear goes pub­lic, rais­ing $175 mil­lion (phar­mafo­rum): Pear will make its debut on the exchange today after com­bin­ing with Thim­ble Point – a spe­cial pur­pose acqui­si­tion com­pa­ny (SPAC) – in a deal that side­stepped the con­ven­tion­al ini­tial pub­lic offer­ing (IPO) route and has pro­pelled its val­u­a­tion to around $1.6 bil­lion … Pear specialises…

Read More

Trend: Harnessing digital tech to improve mental health and wellness

By SharpBrains | October 25, 2021

From mind­ful­ness apps to vir­tu­al ther­a­py ses­sions, dig­i­tal tools offer instant access to well­ness resources (The Globe and Mail): In 2015, Brie Code was work­ing at lead­ing video game com­pa­ny Ubisoft as lead arti­fi­cial intel­li­gence pro­gram­mer when she real­ized that many peo­ple she knew – about half, by her esti­ma­tion – found video games boring.

Read More

The FDA clears Somryst, Pear’s digital therapeutic to treat chronic insomnia

By SharpBrains | March 30, 2020

Pear gets FDA clear­ance for insom­nia ther­a­peu­tic (Med­C­i­ty News): “Pear Ther­a­peu­tics received mar­ket­ing autho­riza­tion for its third prod­uct — a dig­i­tal ther­a­peu­tic intend­ed to treat chron­ic insom­nia. Called Som­ryst, the app is avail­able by pre­scrip­tion only. It con­sists of a nine-week pro­gram that includes cog­ni­tive behav­ioral ther­a­py and restrict­ing sleep to a lim­it­ed win­dow of time

Read More

Trend: Pharma industry warming up to digital therapeutics

By SharpBrains | August 22, 2019

Dig­i­tal ther­a­peu­tics have poten­tial but com­mer­cial suc­cess unproven (Van­tage): “Devel­op­ing drugs to treat dis­or­ders of the cen­tral ner­vous sys­tem is famous­ly fraught with dif­fi­cul­ty. Sev­er­al com­pa­nies, includ­ing Pear Ther­a­peu­tics and Dthera, are tak­ing a wild­ly dif­fer­ent approach: dig­i­tal ther­a­peu­tics. These are pieces of soft­ware designed to treat dis­ease that are reg­u­lat­ed, pre­scribed and even paid…

Read More

Can digital Cognitive Behavioral Therapy (CBTi) become the universal first-line treatment for insomnia?

By SharpBrains | August 13, 2019

__________ Pear Ther­a­peu­tics’ dig­i­tal insom­nia ther­a­peu­tic will put FDA’s Pre­Cert frame­work through its paces (Mobi­Health­News): “Pre­scrip­tion dig­i­tal ther­a­peu­tics com­pa­ny Pear Ther­a­peu­tics announced late last week that it has filed an FDA mar­ket­ing autho­riza­tion for Som­ryst, its dig­i­tal cog­ni­tive behav­ioral ther­a­py for the treat­ment of adults with chron­ic insom­nia and depres­sion. While an approval from the…

Read More